ValuEngine downgraded shares of Insmed (NASDAQ:INSM) from a strong-buy rating to a buy rating in a report issued on Tuesday morning.
A number of other research analysts have also issued reports on the stock. Morgan Stanley boosted their price target on shares of Insmed from $37.00 to $39.00 and gave the stock an overweight rating in a research note on Monday, August 6th. JMP Securities lowered shares of Insmed from an outperform rating to a market perform rating in a research note on Monday, August 6th. Zacks Investment Research upgraded shares of Insmed from a sell rating to a hold rating in a research note on Thursday, August 9th. HC Wainwright reiterated a buy rating and set a $43.00 price target on shares of Insmed in a research note on Friday, August 3rd. Finally, Goldman Sachs Group started coverage on shares of Insmed in a research note on Monday, July 23rd. They set a neutral rating and a $32.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $38.43.
Shares of Insmed stock opened at $19.89 on Tuesday. Insmed has a 52-week low of $19.15 and a 52-week high of $33.94. The company has a current ratio of 14.14, a quick ratio of 14.14 and a debt-to-equity ratio of 0.83. The stock has a market cap of $1.57 billion, a PE ratio of -6.89 and a beta of 1.29.
Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.08. equities analysts anticipate that Insmed will post -4.06 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the business. Quantbot Technologies LP grew its position in Insmed by 196.1% during the first quarter. Quantbot Technologies LP now owns 4,841 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 3,206 shares during the period. SG Americas Securities LLC acquired a new position in Insmed during the first quarter worth about $116,000. NumerixS Investment Technologies Inc acquired a new position in Insmed during the second quarter worth about $122,000. Smith Asset Management Group LP acquired a new position in Insmed during the first quarter worth about $166,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Insmed during the second quarter worth about $200,000.
Insmed Company Profile
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.
Recommended Story: Asset Allocation and Your Retirement
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.